대한한의학회지 (The Journal of Korean Medicine)

  • 제43권3호
  • /
  • Pages.16-26
  • /
  • 2022
  • /
  • 1010-0695(pISSN)
  • /
  • 2288-3339(eISSN)
대한한의학회 (The Society of Korean Medicine)
권호 표지
DOI QR코드

DOI QR Code

The Retrospective Study of Advanced Cancer Patients Receiving Integrative Cancer Treatments in single Comprehensive and Integrative Medicine Hospital

  • Jeonghyun Joo (Integrative Cancer Center, CHA University Ilsan Medical Center ) ;
  • Songha Chon (Integrative Cancer Center, CHA University Ilsan Medical Center ) ;
  • Kicheul Sohn (Department of Preventive Medicine, Daegu Catholic University Medical Center) ;
  • Sanghun Lee (Department of Bioconvergence & Engineering, Graduate school, Dankook University)
  • 투고 : 2022.04.01
  • 심사 : 2022.07.04
  • 발행 : 2022.09.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: Traditional Korean medicine (TKM) has been supplied as part of a national health care system in South Korea under a dual medical system, however it has been difficult to mix western medicine and TKM medical practices in existing hospitals. For the objective of innovative integration between them, Comprehensive and Integrative Medicine Hospital were founded in Daegu, South Korea. Here, we discussed the clinical outcomes of cancer patients who received integrative cancer treatment (ICT). Methods: A total of 678 patients previously diagnosed with cancer were retrospectively checked in our institution for 2 years. After applying inclusion/exclusion criteria, 573 patients were eligible for the final analysis. The overall survival (OS) of these patients in the aftercare period were determined. We looked at how clinical factors and treatments including chemotherapy, complementary and alternative medicine (CAM), and TKM affected the OS. Results: At the first visit, 212 subjects had no evidence of disease after tumor resection and 355 ones with advanced cancer, who receiving ICT including chemotherapy, CAM, and TKM showed better OS compared to the CAM including TKM or the best supportive care (median OS = 216, 78, and 46 days, respectively). The median OS was not reached in TKM only, even though the sample size was small (N=12). Even after adjusting for clinical factors associated to liver, renal, and hematologic manifestation, ICT still remained significant. Conclusions: We demonstrated that ICT might be beneficial for advanced cancer regardless of the performance status, liver and renal function, since it positively affected the OS.

키워드

과제정보

This work was supported by a grant from the Comprehensive and Integrative Medicine R&D project through Comprehensive and Integrative Medicine Institute, funded by the Ministry of Health & Welfare, Republic of Korea (Grant Number: 090-091-3000-3038-301-320-01).

참고문헌

  1. Zhang, Q.Sharan, A.Espinosa, S. A.Gallego-Perez, D. & Weeks, J. (2019). The path toward integration of traditional and complementary medicine into health systems globally: The world health organization report on the implementation of the 2014-2023 strategy. J Altern Complement Med. 25(9). 869-871. 10.1089/acm.2019.29077.jjw
  2. Brinkhaus, B. (2010). New perspectives in medicine are required - from cam to integrative medicine. Forsch Komplementmed. 17(4). 216. 10.1159/000295165
  3. Yun, H.Sun, L. & Mao, J. J. (2017). Growth of integrative medicine at leading cancer centers between 2009 and 2016: A systematic analysis of nci-designated comprehensive cancer center websites. J Natl Cancer Inst Monogr. 2017(52). 10.1093/jncimonographs/lgx004
  4. Desai, K.Liou, K.Liang, K.Seluzicki, C. & Mao, J. J. (2021). Availability of integrative medicine therapies at national cancer institute-designated comprehensive cancer centers and community hospitals. J Altern Complement Med. 27(11). 1011-1013. 10.1089/acm.2021.0102
  5. Deng, G. E., Rausch, S. M., Jones, L. W., Gulati, A., Kumar, N. B., Greenlee, H., et al. (2013). Complementary therapies and integrative medicine in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 143(5 Suppl). e420S-e436S. 10.1378/chest.12-2364
  6. Greenlee, H., DuPont-Reyes, M. J., Balneaves, L. G., Carlson, L. E., Cohen, M. R., Deng, G., et al. (2017). Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 67(3). 194-232. 10.3322/caac.21397
  7. Park, J.Yi, E. & Yi, J. (2021). The provision and utilization of traditional korean medicine in south korea: Implications on integration of traditional medicine in a developed country. Healthcare (Basel). 9(10). 10.3390/healthcare9101379
  8. Lee, S.Joo, J. & Chon, S. (2018). Successful outcome of an elderly patient with small cell lung cancer with only alternative treatments: A case report. The Journal of Korean Medicine. 39(4). 171-176. http://dx.doi.org/10.13048/jkm.18043
  9. Lee, S.Sohn, K. & Chon, S. (2018). Successful outcome of breast cancer patient refusing conventional treatments: A case report. The Journal of Korean Medicine. 39(4). 177-182. http://dx.doi.org/10.13048/ jkm.18044
  10. Garaci, E., Pica, F., Serafino, A., Balestrieri, E., Matteucci, C., Moroni, G., et al. (2012). Thymosin alpha1 and cancer: Action on immune effector and tumor target cells. Ann N Y Acad Sci. 1269(26-33). 10.1111/j.1749-6632.2012.06697.x
  11. Evans, M.Bryant, S.Huntley, A. L. & Feder, G. (2016). Cancer patients' experiences of using mistletoe (viscum album): A qualitative systematic review and synthesis. J Altern Complement Med. 22(2). 134-144. 10.1089/acm.2015.0194
  12. Barchielli, G.Capperucci, A. & Tanini, D. (2022). The role of selenium in pathologies: An updated review. Antioxidants (Basel). 11(2). 10.3390/antiox 11020251
  13. Kennedy, L.Sandhu, J. K.Harper, M. E. & Cuperlovic-Culf, M. (2020). Role of glutathione in cancer: From mechanisms to therapies. Biomolecules. 10(10). 10.3390/biom10101429
  14. Bottger, F.Valles-Marti, A.Cahn, L. & Jimenez, C. R. (2021). High-dose intravenous vitamin c, a promising multi-targeting agent in the treatment of cancer. J Exp Clin Cancer Res. 40(1). 343. 10.1186/s13046 -021-02134-y
  15. Cheng, Y., Weng, S., Yu, L., Zhu, N., Yang, M. & Yuan, Y. (2019). The role of hyperthermia in the multidisciplinary treatment of malignant tumors. Integr Cancer Ther. 18(1534735419876345. 10.1177/1534735419876345
  16. Survey report on utilization of traditional korean medicine 2020. National Institute of Korean Medicine Development, Korean Ministry of Health and Welfare. https://www.koms.or.kr/board/researchReport/view.do?post_no=161&menu_no=21.
  17. Jung, K. W.Won, Y. J.Kong, H. J. & Lee, E. S. (2019). Cancer statistics in korea: Incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat. 51(2). 417-430. 10.4143/crt.2019.138
  18. Bae, K.Kim, E.Choi, J. J.Kim, M. K. & Yoo, H. S. (2018). The effectiveness of anticancer traditional korean medicine treatment on the survival in patients with lung, breast, gastric, colorectal, hepatic, uterine, or ovarian cancer: A prospective cohort study protocol. Medicine (Baltimore). 97(41). e12444. 10.1097/MD.0000000000012444
  19. Choi, W., Jung, H., Kim, K., Lee, S., Yoon, S., Park, J., et al. (2012). Rhus verniciflua stokes against advanced cancer: A perspective from the korean integrative cancer center. J Biomed Biotechnol. 2012(874276. 10.1155/2012/874276
  20. Kim, Y. (2014). Towards universal coverage: An evaluation of the benefit enhancement plan for four major conditions in korean national health insurance. J Korean Med Assoc. 57(3). 198-203. 10.5124/jkma.2014.57.3.198
  21. Hung, K. F., Hsu, C. P., Chiang, J. H., Lin, H. J., Kuo, Y. T., Sun, M. F., et al. (2017). Complementary chinese herbal medicine therapy improves survival of patients with gastric cancer in taiwan: A nationwide retrospective matched-cohort study. J Ethnopharmacol. 199 (168-174). 10.1016/j.jep.2017.02.004
  22. Wang, C. Y., Huang, H. S., Su, Y. C., Tu, C. Y., Hsia, T. C. & Huang, S. T. (2018). Conventional treatment integrated with chinese herbal medicine improves the survival rate of patients with advanced non-small cell lung cancer. Complement Ther Med. 40(29-36. 10.1016/j.ctim.2018.07.003
  23. Ling, C. Q., Fan, J., Lin, H. S., Shen, F., Xu, Z. Y., Lin, L. Z., et al. (2018). Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional chinese and western medicine. J Integr Med. 16(4). 236-248. 10.1016/j.joim.2018.05.002
  24. Yeh, M. H., Chiu, H. P., Wu, M. C., Koo, M., Lin, N. W., Liao, K. K., et al. (2020). Integrated chinese herbal medicine and western medicine on the survival in patients with colorectal cancer: A retrospective study of medical records. Evid Based Complement Alternat Med. 2020(456-1040). 10.1155/2020/4561040
  25. Lee, Y. C.Chen, Y. H.Huang, Y. C.Lee, Y. F. & Tsai, M. Y. (2020). Effectiveness of combined treatment with traditional chinese medicine and western medicine on the prognosis of patients with breast cancer. J Altern Complement Med. 26(9). 833-840. 10.1089/acm.2019.0200
  26. Bae, K., Kim, E., Kong, J. S., Kim, J., Park, S. J., Jun, H. J., et al. (2019). Integrative cancer treatment may have a survival benefit in patients with lung cancer: A retrospective cohort study from an integrative cancer center in korea. Medicine (Baltimore). 98(26). e16048. 10.1097/MD.0000000000016048
  27. Wang, Y., Liu, P., Fang, Y., Tian, J., Li, S., Xu, J., et al. (2020). The effect of long-term traditional chinese medicine treatment on survival time of colorectal cancer based on propensity score matching: A retrospective cohort study. Evid Based Complement Alternat Med. 2020(702-3420. 10.1155/2020/7023420
  28. Yeh, M. H., Wu, H. C., Lin, N. W., Hsieh, J. J., Yeh, J. W., Chiu, H. P., et al. (2020). Long-term use of combined conventional medicine and chinese herbal medicine decreases the mortality risk of patients with lung cancer. Complement Ther Med. 52(102-427). 10.1016/j.ctim.2020.102427
  29. Euser, A. M.Zoccali, C.Jager, K. J. & Dekker, F. W. (2009). Cohort studies: Prospective versus retrospective. Nephron Clin Pract. 113(3). c214-217. 10.1159/000235241